Dose Ranging Study of Pazopanib to Treat Neovascular Age-Related Macular Degeneration

MD7110852 is a Phase 2b dose-ranging study designed to demonstrate the 1 year efficacy and
safety of pazopanib eye drops for the treatment of neovascular age related macular
degeneration (AMD) in subjects whose disease is currently managed with anti-VEGF (vascular
endothelial growth factor) injection therapy. Eye drop regimens are double-masked with
placebo eye drops and will have access to open-label ranibizumab intravitreal (IVT) injection
if needed. The ranibizumab IVT injection every 4 weeks control arm is open-label.

Inclusion Criteria:

- Men and women aged ≥50 years.

- Active subfoveal choroidal neovascularization (CNV) lesion secondary to AMD in study
eye: Total lesion area ≤12 disc areas with CNV ≥50% total lesion area.

- Anti-Vascular endothelial growth factor (VEGF) intravitreal injection experienced and
in need of re-treatment.

- Best-corrected visual acuity of at least 24 letters (equates to approximately 20/320
Snellen equivalents or better).

Exclusion Criteria:

- Prior ocular investigational drug/device for choroidal neovascularization,
photodynamic therapy, radiation, subfoveal or juxtafoveal focal laser
photocoagulation.

- Prior failure to anti-VEGF intravitreal injection therapy.

- Recent ocular investigational drug/device for non-CNV condition.

- Prior ocular surgeries (vitrectomy, scleral buckle, or glaucoma filtering/shunt
surgery). Cataract surgery permitted if ≥3 months and has posterior chamber
intraocular lens.

- Center-fovea involvement of any of the following: fibrosis, atrophy, serous retinal
pigment epithelial detachment, or retinal pigment epithelial tear.

- CNV in either eye due to other causes.

- Clinical evidence of diabetic retinopathy or diabetic macular edema.

- Recent myocardial infarction or cerebrovascular accident.

- Uncontrolled hypertension in spite of antihypertensive medications.